Alembic [APLLTD] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Alembic Pharmaceuticals Ltd.

NSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Alembic Pharmaceuticals Ltd. wins in 7 metrics, Divi's Laboratories Ltd. wins in 13 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Alembic Pharmaceuticals Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 23.42 67.11 Alembic Pharmaceuticals Ltd.
Price-to-Book Ratio 2.77 10.82 Alembic Pharmaceuticals Ltd.
Debt-to-Equity Ratio 28.00 0.58 Divi's Laboratories Ltd.
PEG Ratio -1.77 4.63 Divi's Laboratories Ltd.
EV/EBITDA 14.29 48.63 Alembic Pharmaceuticals Ltd.
Profit Margin (TTM) 8.66% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) 11.37% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) 11.37% 29.65% Divi's Laboratories Ltd.
Return on Equity 11.24% 14.64% Divi's Laboratories Ltd.
Return on Assets (TTM) 7.51% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $-4.76B $2.15B Divi's Laboratories Ltd.
Dividend Yield 1.09% 0.91% Alembic Pharmaceuticals Ltd.
1-Year Return -27.70% 0.83% Divi's Laboratories Ltd.
Price-to-Sales Ratio (TTM) 2.03 16.18 Alembic Pharmaceuticals Ltd.
Enterprise Value $161.16B $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 2.22 15.86 Alembic Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 71.81% 63.71% Alembic Pharmaceuticals Ltd.
Revenue per Share (TTM) $371 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $32.07 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.34 0.19 Divi's Laboratories Ltd.

Alembic Pharmaceuticals Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

APLLTD
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Alembic Pharmaceuticals Ltd.1.93%-4.06%-5.51%3.62%-20.45%-13.62%
Divi's Laboratories Ltd.0.30%-3.25%-0.65%4.12%1.88%3.66%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Alembic Pharmaceuticals Ltd.-27.70%32.91%-22.47%32.57%1,483.01%1,483.01%
Divi's Laboratories Ltd.0.83%89.86%56.44%484.44%1,625.50%9,907.51%

Performance & Financial Health Analysis: Alembic Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricAPLLTDDIVISLAB
Market Information
Market Cap i₹147.63B₹1.69T
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i75,949253,443
90 Day Avg. Volume i103,405283,911
Last Close₹737.55₹6,596.50
52 Week Range₹635.80 - ₹1,107.90₹5,636.50 - ₹7,071.50
% from 52W High-33.43%-6.72%
All-Time High₹1,303.90 (Oct 07, 2024)₹7,071.50 (Jul 08, 2025)
% from All-Time High-43.44%-6.72%
Growth Metrics
Quarterly Revenue Growth0.11%0.12%
Quarterly Earnings Growth-0.04%-0.01%
Financial Health
Profit Margin (TTM) i0.09%0.24%
Operating Margin (TTM) i0.11%0.30%
Return on Equity (TTM) i0.11%0.15%
Debt to Equity (MRQ) i28.000.58
Cash & Liquidity
Book Value per Share (MRQ)₹270.70₹580.95
Cash per Share (MRQ)₹7.27₹122.95
Operating Cash Flow (TTM) i₹-3,101,700,000₹19.67B
Levered Free Cash Flow (TTM) i₹5.83B₹21.91B
Dividends
Last 12-Month Dividend Yield i1.09%0.91%
Last 12-Month Dividend i₹11.00₹60.00

Valuation & Enterprise Metrics Analysis: Alembic Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricAPLLTD (Apr 26, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i23.4267.11
Forward P/E i17.7553.75
PEG Ratio i-1.774.63
Price to Sales (TTM) i2.0316.18
Price to Book (MRQ) i2.7710.82
Market Capitalization
Market Capitalization i₹147.63B₹1.69T
Enterprise Value i₹161.16B₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i2.2215.86
Enterprise to EBITDA i14.2948.63
Risk & Other Metrics
Beta i0.340.19
Book Value per Share (MRQ) i₹270.70₹580.95

Financial Statements Comparison: Alembic Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAPLLTD (2025)DIVISLAB (2025)
Revenue/Sales i65.40B93.25B
Cost of Goods Sold i21.37B38.70B
COGS % of Revenue i32.7%41.5%
Gross Profit i44.03B54.55B
Gross Margin i67.3%58.5%
Research & Development i96.00M270.00M
Operating Income (EBIT) i7.35B25.71B
Operating Margin i11.2%27.6%
EBITDA i10.52B33.19B
EBITDA Margin i16.1%35.6%
Pre-Tax Income i7.07B29.16B
Pre-Tax Income % of Revenue i10.8%31.3%
Income Tax i1.25B7.25B
Income Tax % of Revenue i1.9%7.8%
Net Income (Profit) i5.82B21.91B
Profit Margin i8.9%23.5%

Balance Sheet & Liquidity Metrics

MetricAPLLTD (2025)DIVISLAB (2025)
Cash & Equivalents i834.80M4.15B
Total Current Assets i40.88B100.81B
Total Current Assets % of Revenue i62.5%108.1%
Total Current Liabilities i24.12B14.52B
Total Current Liabilities % of Revenue i36.9%15.6%
Long-Term Debt i467.70M20.00M
Long-Term Debt % of Revenue i0.7%0.0%
Total Shareholders Equity i51.90B149.69B
Retained Earnings i43.94B134.00B
Retained Earnings % of Revenue i67.2%143.7%
Property, Plant & Equipment i4.45B3.19B

Cash Flow Statement Comparison

MetricAPLLTD (2025)DIVISLAB (2025)
Operating Cash Flow i-3.10B19.67B
Operating Cash Flow % of Revenue i-4.7%21.1%
Capital Expenditures i-5.54B-14.38B
Free Cash Flow i-4.76B2.15B
FCF Margin i-7.3%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricAPLLTDDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i196.56M265.47M
Float Shares i57.90M117.72M
% Held by Insiders i70.56%52.04%
% Held by Institutions i16.81%28.65%
% Held by Public i12.63%19.31%

Dividend Analysis & Yield Comparison: Alembic Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricAPLLTDDIVISLAB
Last 12-Month Dividend i₹11.00₹60.00
Last 12-Month Dividend Yield i1.09%0.91%
3-Year Avg Annual Dividend i₹13.33₹50.00
3-Year Avg Dividend Yield i1.17%0.70%
3-Year Total Dividends i₹40.00₹150.00
Ex-Dividend DateJul 29, 2025Jul 25, 2025